- Report
- October 2025
- 193 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1424EUR$1,600USD£1,253GBP
€1780EUR$2,000USD£1,567GBP
- Report
- January 2025
- 175 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Report
- June 2024
- 200 Pages
Global
From €5660EUR$6,360USD£4,982GBP
€7074EUR$7,950USD£6,227GBP
- Report
- January 2022
- 60 Pages
Global
From €2812EUR$3,160USD£2,475GBP
€3515EUR$3,950USD£3,094GBP
- Report
- May 2024
- 128 Pages
Global
From €4916EUR$5,524USD£4,327GBP
€5783EUR$6,499USD£5,091GBP
- Report
- September 2022
- 38 Pages
Global
From €1780EUR$2,000USD£1,567GBP
Impetigo is a contagious skin infection caused by bacteria. It is most common in children, but can affect people of any age. Treatment for impetigo typically involves antibiotics, either topical or oral. The Impetigo Drug market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat a wide range of bacterial, viral, and fungal infections.
The Impetigo Drug market is composed of a variety of antibiotics, including penicillin, cephalosporins, macrolides, and sulfonamides. These drugs are used to treat the infection and reduce the risk of complications. In addition, some drugs are used to reduce the risk of recurrence.
The Impetigo Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, Novartis, and Johnson & Johnson. Show Less Read more
